Conclusion: Overall, the company's branding strategy has taken a solid first step. The variety of iHealth products is getting richer, and I believe that with the further improvement of sales channels in the US, 2012 is likely to usher in a good year. Since the current order situation is uncertain, we temporarily maintain our 2011-2013 profit forecasts for EPS of 0.16, 0.23, and 0.32 yuan. The PE corresponding to the current stock price of 8.53 yuan is 53 times, 37 times, and 27 times. We emphasize that due to the high uncertainty of the new business, the company's performance is very flexible (see Table 1). Maintain the company's “Recommended” rating for the time being. For the basic situation of Jiu'an Healthcare and our long-term views on Jiu'an Healthcare, please refer to the Dongxing Securities Research Report “Jiu'an Healthcare (002432): Traditional Businesses Are Gradually Resuming, Innovative Models Are Being Searched”, “Jiu'an Healthcare (002432): Brands Affected by Exports Should Be Strong”, “Jiu'an Healthcare (002432): Focusing on the Long-Term Layout of the United States”, “Jiu'an Healthcare (002432): A Strong Look at Japan”, and “Jiu'an Healthcare (002432): A Strong Look at Japan”, and “Jiu'an Healthcare (002432): A Strong Look at Japan”, and “Jiu'an Healthcare (002432): A Strong Look at the Future of China”, and “Jiu'an Healthcare (002432): Little People Are Sharp”.